Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era

ABSTRACT

People with multiple sclerosis (MS) are at risk for infections that can result in amplification of baseline symptoms and possibly trigger clinical relapses. Vaccination can prevent infection through the activation of humoral and cellular immune responses. This is particularly pertinent in the era of emerging novel vaccines against severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease 2019 (COVID-19). MS disease-modifying therapies (DMTs), which affect the immune system, may impact immune responses to COVID-19 vaccines in people with MS. The objective of this article is to provide information on immune system responses to vaccinations and review previous studies of vaccine responses in people with MS to support the safety and importance of receiving currently available and emerging COVID-19 vaccines. Immunological studies have shown that coordinated interactions between T and B lymphocytes of the adaptive immune system are key to successful generation of immunological memory and production of neutralizing antibodies following recognition of vaccine antigens by innate immune cells. CD4+ T cells are essential to facilitate CD8+ T cell and B cell activation, while B cells drive and sustain T cell memory. Data suggest that some classes of DMT, including type 1 interferons and glatiramer acetate, may not significantly impair the response to vaccination. DMTs—such as sphingosine-1-phosphate receptor modulators, which sequester lymphocytes from circulation; alemtuzumab; and anti-CD20 therapies, which rely on depleting populations of immune cells—have been shown to attenuate responses to conventional vaccines. Currently, three COVID-19 vaccines have been granted emergency use authorization in the USA on the basis of promising interim findings of ongoing trials. Because analyses of these vaccines in people with MS are not available, decisions regarding COVID-19 vaccination and DMT choice should be informed by data and expert consensus, and personalized with considerations for disease burden, risk of infection, and other factors.
Key Summary Points

People with multiple sclerosis (MS) may be at increased risk for infection, which can lead to relapses or pseudo-relapses.

Vaccines are an important health measure to prevent infections and require activation of humoral and cellular immune responses.

Some disease-modifying therapies (DMTs) for MS—including sphingosine-1-phosphate receptor modulators, which sequester lymphocytes from circulation; alemtuzumab (anti-CD52); anti-CD20 therapies; and cladribine (impairs DNA synthesis)—exert effects on humoral and cellular immune activity that may affect the response to available and emerging coronavirus disease 2019 (COVID-19) vaccines.

Coordinated interactions between T and B lymphocytes of the adaptive immune system are integral to the successful generation of immunological memory and the production of neutralizing antibodies.

Risks versus benefits of timing vaccinations to ensure maximum vaccine efficacy, as outlined in vaccination guidance and guidelines developed by national and international MS groups, should be considered in the decision to receive a COVID-19 vaccine—even if efficacy may be compromised—when disease burden is high.

INTRODUCTION

Multiple sclerosis (MS) is an inflammatory, demyelinating, neurodegenerative disease of the central nervous system that causes significant and irreversible neurological disability [1, 2]. An estimated 2.8 million people are living with MS worldwide, including almost 1 million people in the USA; global prevalence in 2020 was 35.9 per 100,000 persons and is expected to rise [3, 4]. Although the etiology of MS is unknown, a number of environmental, genetic, and epigenetic factors are believed to contribute to immunopathogenesis of MS [5].

People with MS are at increased risk for acquiring certain types of infections, including respiratory and other viral and bacterial infections [6–8]. Additionally, certain disease-modifying therapies (DMTs), which suppress or alter the immune system, have been associated with increased risk of upper respiratory tract infections, urinary tract infections, and other infections [9]. This is relevant for people with MS because bacterial and viral infections have been shown to be associated with new or worsening baseline MS symptoms in the form of relapses or pseudo-relapses [10]. Upper respiratory tract infections can double the risk for relapse [11]. Furthermore, increased rates of influenza in the general population are temporally associated with a greater occurrence of relapses in people with MS [12]. It is speculated that relapses associated with an infection can be more neurologically damaging than those unrelated to infection [13]. Therefore, measures to prevent infection are particularly important for people with MS.

Over the years, there have been numerous iterations of consensus statements regarding the risks and benefits of vaccination in people with MS [14–20]. National and international guidance and guidelines generally agree that the benefits of vaccination outweigh any potential risks. The only exception is with live attenuated vaccines, which should not be used in people...
who are currently receiving or have recently discontinued immunosuppressive or immunomodulating DMTs, unless the risk of infection is elevated and nonlive vaccines are not available. The reason for this is that a live virus or bacteria has the potential to cause an infection and if the vaccine is administered during treatment with a MS DMT, the ability of the immune response to clear the infection could be impaired, which could possibly result in worsening of MS symptoms. Some DMTs exert effects on humoral and cellular immune activity that may affect the response to vaccination [21, 22].

Data on the efficacy of vaccinations in people with MS receiving immunosuppressive or immunomodulatory DMTs are still lacking, leading to a great deal of variability at the local, national, and international level with regard to vaccine guidance and guidelines [15–17, 19]. A better understanding of how DMTs for MS may influence vaccine safety and efficacy has become even more urgent given the current coronavirus disease 2019 (COVID-19) pandemic and recent authorization of vaccines specific for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19.

The incidence of COVID-19 in people with MS ranges from below 1% to 11% (including suspected but not confirmed cases) in studies that included a cross-sectional mixed method study, retrospective cohort analysis, and a prospective observational cohort study compared with World Health Organization (WHO) estimates of 1432 per 100,000 globally, and 8424 per 100,000 in the USA in the general population [23–26]. COVID-19-related MS mortality has been reported to be approximately 1–4% overall (compared with a case–fatality ratio in the general population of 0.0–9.2% in the 20 countries most affected by COVID-19, including the USA, which has a rate of 1.8% [according to Johns Hopkins University]), and more than 50% of deaths have occurred in people not receiving MS DMTs [27–29]. An analysis of data in people with MS from 28 countries who had suspected or confirmed COVID-19 found that treatment with ocrelizumab or rituximab was associated with significantly increased risk of hospitalization and admission to the intensive care unit compared with other pooled DMTs (including alemtuzumab, cladribine, dimethyl fumarate, fingolimod, glatiramer acetate, interferon, natalizumab, and teriflunomide) [30]. Rituximab was also associated with significantly increased risk of artificial ventilation [30]. In a recent retrospective study from electronic health records, interferons and glatiramer acetate were shown to be associated with reduced COVID-19 risk, whereas anti-CD20 therapies were associated with increased risk, within the treated MS cohort [31]. In contrast, an analysis of COViMS registry data from 1626 patients with MS found that poorer clinical COVID-19 outcomes (including mortality) were associated with older patient age and greater disability whereas use of rituximab was associated with increased risk of hospitalization [32]. These findings suggest that the use of these anti-CD20 agents could be a risk factor for more severe infection.

Up to 98% of neurologists surveyed were concerned about their patients with MS contracting COVID-19, and 80% thought that certain DMTs would not permit a protective response to a COVID-19 vaccine [33]. Clinicians were most concerned about vaccine response and concomitant treatment with ocrelizumab (84%), rituximab (83%), and alemtuzumab (78%) [33], suggesting that prolonged T and B cell depletion is an important consideration. However, there may be an optimal timing of vaccination with some DMTs in order to achieve the best vaccine immune response.

This review will discuss the immune system, immunological effects of vaccination, existing data on the effects of DMTs on vaccination efficacy, and vaccine considerations in people with MS as they relate to currently available and emerging COVID-19 vaccines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Table 1 Types of vaccines

| Vaccine type               | MOA/effect                                                                 | Examples                      |
|----------------------------|-----------------------------------------------------------------------------|-------------------------------|
| Major types [47]           |                                                                             |                               |
| Live attenuated [40, 48]   | Weakened version of the pathogen                                            | Smallpox                      |
|                            | Cause CD8\(^+\) cytotoxic T cell generation and recruitment of antigen-specific CD4\(^+\) T helper cells (i.e., a T-dependent antibody response) | Yellow fever                  |
|                            | Confer immunity that lasts for decades                                      | Measles                       |
|                            | Generally contraindicated in those with weakened immune systems             | Chicken pox                   |
|                            |                                                                             | Oral polio vaccine            |
| Inactivated whole cell [36, 48, 49] | More stable and safer than live vaccines, as dead microbe cannot mutate back to its virulent form | Inactivated polio             |
|                            | Often poorly immunogenic and require additives, such as aluminum salts, oil-in-water emulsions, and saponins to help stimulate antibody and effector T cell immune functions | Whole cell polio              |
|                            | Protection may be of shorter duration; booster vaccinations may be required |                               |
| Subunit (purified antigen) [40, 47–51] | Include protein-based, polysaccharide, and conjugate types | Acellular pertussis (aP)       |
|                            | Often poorly immunogenic and require additives, such as aluminum salts, oil-in-water emulsions, and saponins to help stimulate antibody and effector T cell immune functions | Haemophilus influenzae type b (Hib) |
|                            | Can contain up to 20 antigenic determinants, i.e., epitopes of the antigen that are recognized by antibodies and T cells | Pneumococcal (PCV-7, PCV-10, PCV-13) |
|                            | Reversion to a virulent form cannot occur                                   | Hepatitis B (HepB)            |
|                            | Determination of antigen combinations must be made to elicit effective immune response | COVID-19                      |
The immune system is composed of two arms: the innate system and the adaptive or acquired system. It is the complex interplay between these two arms that comprises the normal immunological response to foreign antigens. The innate immune system is the first line of defense against infection; it plays a crucial role...
in the initial recognition of pathogens and in the activation of the cells of the adaptive immune system. Cells that are involved in innate immune responses include monocytes/macrophages, dendritic cells, mast cells, neutrophils, eosinophils, natural killer cells, and natural killer T cells [34]. These cells express receptors such as pattern recognition receptors, which are not specific to any particular pathogen and allow the cells to react to microbes containing common molecular structures, and pathogen-associated molecular patterns, including liposaccharides, other bacterial cell wall components, and virus-derived double-stranded RNA [35]. Innate immune responses occur more rapidly than adaptive immune responses and are generated within minutes to hours of infection [36]. However, subsequent encounters with the same pathogen will not elicit a faster or stronger response (i.e., no innate immunological memory is created) [36].

The Adaptive Immune System

The adaptive immune system is activated 4–7 days after exposure to a pathogen [37] in response to interactions between antigens, antigen receptor-bearing lymphocytes (T cells), and antigen-presenting cells (APCs); the latter-most can be specific cells of the innate immune system or B cells (Fig. 1) [37, 38]. The coordinated interactions between T and B lymphocytes of the adaptive immune system are integral to the immune system’s response when called into action by the innate immune cells [39]. Both T and B cells express unique antigen-binding receptors on their cell membranes [35]. Each cell expresses a single type of receptor and has the ability to rapidly proliferate and differentiate when activated.

Cellular Response

T cells mediate the cellular immune response [40–42]. They are activated by APCs that have digested an antigen and are displaying a peptide from the antigen on their membrane (bound by major histocompatibility complex molecules) [35]. Specific subtypes of T cell are produced and have differentiated functions, including CD8+ (cytotoxic T cells), CD4+ (helper T cells), and follicular T helper cells, among others [40]. CD8+ T cells reduce, control, and eliminate intracellular pathogens by directly (via release of perforin, granzyme, etc.) or indirectly (via antimicrobial cytokine release) killing infected cells [40]. CD4+ T cells are involved in the reduction, control, and clearance of extracellular and intracellular pathogens. This occurs through the release of cytokines that support the activation and differentiation of B cells, CD8+ T cells, and macrophages, contributing to defense against bacteria and viruses on mucosal surfaces [40]. Subsets of CD4+ T cells include T helper 1, 2, 9, and 17 cells; regulatory T cells; and, as mentioned previously, follicular T helper cells [43], which provide an intricate and highly specific response to the pathogen.
Humoral Response

The cellular immunity that is achieved by the differentiation and production of antigen-specific T cell populations is important, but it is only one part of the adaptive immune response. The other part is humoral immunity, which is composed of B cells, the complement system, and antibodies [38, 40, 44].

B cells are activated by cytokines released by T helper cells (e.g., interleukin [IL]-4, IL-5, IL-13) and upon activation differentiate into plasma cells, which produce antibodies [37, 40, 45]. B cells can also recognize antigens directly, without the involvement of APCs of the innate immune system [35]. Antibodies stop or reduce infections via clearance of extracellular pathogens through binding to the enzymatic active sites of toxins or preventing their diffusion, by neutralizing viral cell entry, promoting phagocytosis of extracellular bacteria, and activating the complement cascade [40]. Additionally, B cells play a role in the further activation of T cells and are involved in both antigen presentation to T cells and the generation of immunological memory [46]. Immunological memory is the capability of the immune system to respond more quickly and effectively to pathogens encountered earlier, and is based on persistent populations of clonally expanded, specialized memory T and B cells [37]. Complement factors opsonize antigens, which can then stimulate the complement receptor 2 expressed on B cells and lower the threshold for producing neutralizing antibodies [44].

Vaccine-Related Immune Response

Vaccines exert their effects through the immune system and rely on both the innate and adaptive arms interacting in a complex and complementary fashion with the goal of generating immunological memory [35]. A variety of vaccine types exist, as shown in Table 1, and they elicit varying degrees of long-term immunological response.

In response to vaccination, the innate, humoral (B cell mediated), and cellular (T cell mediated) immune pathways are activated through multiple steps (Fig. 1) [42, 45]. Initially, inflammation occurs at the site of administration, which can be intramuscular, subcutaneous, oral, or pulmonary/nasal, and is followed by activation of the innate system [45, 63]. The site of administration can affect the immune response [64]. For example, immunization via parenteral administration can fail to induce mucosal immunity [63], while pulmonary/nasal administration of experimental nanoparticle vaccination has resulted in high-frequency, long-lasting, antigen-specific effector memory T cell response at mucosal sites and increased antigen transport [65].

Following vaccine administration, the delivery of vaccine antigens by APCs to activate and recruit CD4⁺ T cells results in T and B cell interaction and the first step of the antibody response: B cell proliferation, maturation, and differentiation into plasma cells [40, 45]. However, the resulting antibodies have low affinity for the antigen, and the response is short-lived. This is followed by the effector phase of the response, which involves the production of higher-affinity antibodies by B cells, differentiation and proliferation of effector T cells [40], and generation of immunological memory, allowing a more rapid and efficient response when the target pathogen is encountered at a later time [37]. B cells are then involved in modulating the contraction of CD8⁺ T cell responses following immunization and in generating memory T cells [46]. Follicular T helper cells are integral to B cell activation or differentiation into memory and plasma cells and in the generation of long-lived antibody responses [66]. The role of follicular T helper cells in the response to vaccination is especially important in the context of therapies for MS that alter or deplete certain immune cell populations. If the follicular T helper cell response is suppressed, complete seroprotection is unlikely to be achieved with a vaccine or even repeated vaccination. Nevertheless, partial seroprotection could still be enough to prevent contracting the infection of interest and/or preventing severe complications from the infection.

The US Centers for Disease Control and Prevention frequently updates the recommendations for adults receiving routine
vaccinations to prevent 17 vaccine-preventable diseases [67]. Recommendations are made on the basis of the effectiveness of the vaccines, which is assessed by humoral response (i.e., the presence of antigen-specific antibody titers) [68]. The hemagglutination inhibition assay, which measures the presence of antibodies to hemagglutinins (which are glycoproteins on the surface of influenza viruses), is one way to measure influenza vaccine response [68, 69]. Typical outcomes seen in clinical trials for vaccines include assessment of antibody titers, seroconversion rates, seroprotection rates (percentages of people developing neutralizing antibodies), functional antibodies (by flow cytometric opsonophagocytosis assays), antibody avidity, B cell and T cell activation, lymphoproliferation, and cytokine responses [70].

However, systems for measuring cellular responses to vaccination are not typically utilized in clinical trials or clinical practice for a number of reasons, including the complexity and cost associated with such assays. For example, US Food and Drug Administration guidelines for influenza vaccine development rely on hemagglutination-inhibiting (HI) antibody titers, i.e., percentage of subjects achieving an HI antibody titer of at least 1:40 and rates of seroconversion (change in titer from less than 1:10 to at least 1:40 or fourfold rise in HI antibody titer) [71]. T cells have been demonstrated to play a role in the immune response to SARS-CoV-2 [72, 73], but such responses are difficult to measure, which has prevented a full understanding of the role of T cells in an effective vaccine response against SARS-CoV-2. Because these data on cellular responses to vaccination are limited, the extent to which any one individual or group of individuals responds to vaccination is difficult to ascertain. In the future, systems biology may be used to analyze early human immune responses to vaccination. Using such approaches, individuals who have been vaccinated may display noticeable and characteristic changes in the gene expression profiles of their peripheral blood leukocytes, allowing for an understanding of the immune response beyond just antibody titers [74].

As treatment of MS evolves toward a personalized approach, immune correlates and how vaccine response is measured—including not only humoral immune responses but also cellular immune responses—may help determine the true differential impact of MS DMTs on vaccine immune response. Moreover, the management of MS may prove to be an incremental burden revolving around treatment choices and timing, if a yearly COVID-19 vaccine or booster becomes necessary.

Individuals may experience diminished protection from vaccines for various reasons. For example, inadequate responses have been reported in people aged over 64 years [75], which may result from immunosenescence stemming from thymic involution, a decrease in naïve T cells, increased T cell memory defects, and impaired ability of B cells to undergo class-switch recombination (i.e., isotype switching), resulting in less diversity of antibodies and decreases in naïve B cells [76]. Other factors that may affect response include sex, obesity, behavior, comorbidities, pregnancy, immunosuppression, and possibly ethnicity [70, 77, 78]. All of these considerations will apply to people with MS as well, and may impact vaccine responsiveness in this population.

GUIDANCE AND GUIDELINES ON VACCINES FROM MS-RELATED SOCIETIES AND ORGANIZATIONS

A number of organizations have made recommendations regarding vaccination for people with MS (Table 2) and, importantly, most point to the lack of high-quality data that can support recommendations [16–18]. The only recommendation by the American Academy of Neurology (AAN) based on the strongest level of evidence (level A) is to screen for certain infections, according to the prescribing information of the particular immunosuppressive or immunomodulating DMT being considered as treatment, and for latent infections in high-risk populations or in countries where specific infections are common [16].

A Delphi consensus statement from a panel of experts and the French Multiple Sclerosis Society (Société Francophone de la Sclérose en
Table 2  Vaccine guidance and guidelines for people with MS

| Guidance/guideline | AAN [16, 79] | MSIF [19]a | NMSS [14, 15, 80]b | MSAA [20]b | SFSEP [17, 81]c | ABN [82]d |
|--------------------|--------------|-------------|-------------------|-------------|-----------------|-----------|
| Live attenuated and killed vaccines | | | | | | |
| Infection screening | ✔ | No guidance | ✔ | ✔ | No guidance | No guidance |
| Discuss available information and patients’ opinions to determine optimal strategy | ✔ | No guidance | ✔ | ✔ | No guidance | No guidance |
| Follow all local vaccine standards | ✔ | No guidance | ✔ | ✔ | ✔ | No guidance |
| Influenza vaccination should be received annually | ✔ | ✔ | ✔ | ✔ | ✔ | No guidance |
| Patients should be counseled about infection risks associated with ISIM therapy and ISIM-specific vaccination guidance | ✔ | No guidance | ✔ | ✔ | ✔ | No guidance |
| Vaccination status should be assessed before prescribing ISIM therapy | ✔ | No guidance | ✔ | ✔ | ✔ | No guidance |
| Vaccination should occur ≥ 4–6 weeks before ISIM therapy initiation | ✔ | No guidance | ✔ | ✔ | No guidance | No guidance |
| Live attenuated vaccines should be avoided while on ISIM therapy or if recently discontinued; if a patient is at high risk of infection and killed vaccines are unavailable, live attenuated vaccines may be considered | ✔ | No guidance | ✔ | ✔ | ✔ | No guidance |
| Vaccination during MS relapse should be delayed | ✔ | No guidance | ✔ | ✔ | ✔ | No guidance |
| COVID-19 mRNA vaccines | | | | | | |
| Discuss available information and patients’ opinions to determine optimal strategy | No | ✔ | ✔ | No guidance | No guidance | ✔d |
| Most people with MS should be vaccinated; vaccination unlikely to trigger MS relapse or worsen chronic symptoms | No | ✔ | ✔ | No guidance | No guidance | ✔d |
| Vaccination can occur while on ISIM therapy | No | ✔ | ✔ | No guidance | ✔ | ✔d |
Plaques) agree with AAN regarding limited studies; and the French Multiple Sclerosis Society recommendations regarding preventative methods are generally similar to those of AAN [17, 18]. The National Multiple Sclerosis Society and Multiple Sclerosis Association of America currently reference AAN and US Centers for Disease Control and Prevention guidance and guidelines and use language from DMT product labels regarding vaccination recommendations [15, 20].

Although robust data to support evidence-based recommendations on COVID-19 vaccinations are not yet available, the Multiple Sclerosis International Federation and the National Multiple Sclerosis Society have

### Table 2 continued

| Guidance/guideline | AAN [16, 79] | MSIF [19]a | NMSS [14, 15, 80]b | MSAA [20]b | SFSEP [17, 81]c | ABN [82]d |
|--------------------|-------------|-----------|-------------------|-----------|----------------|---------|
| Both doses of vaccine should be taken, even if side effects temporarily exacerbate MS symptoms | No guidance | ✓ | ✓ | No guidance | No guidance | ✓ i |
| Data to support evidence-based recommendations on the implications of vaccination for specific neurologic diseases are not yet available | ✓ | ✓ | ✓ | No guidance | ✓ | ✓ i |

**AAN** American Academy of Neurology, **ABN** Association of British Neurologists, **ISIM** immunosuppressive or immunomodulating, **MS** multiple sclerosis, **MSIF** Multiple Sclerosis International Federation, **NMSS** National Multiple Sclerosis Society, **SFSEP** Société Françophone de la Sclérose En Plaques (French Multiple Sclerosis Society)

a COVID-19 mRNA vaccine guidance relates to Pfizer-BioNTech and Moderna

b Refers to AAN guidelines on live attenuated and killed vaccines

c Guidance is associated with immunosuppressive therapy, but no restrictions on vaccination associated with immunomodulators are indicated

d Recommendations are not specific for MS

e Unless there is a specific contraindication

f According to local regulatory standards, guided by treatment-specific infectious risks, and as advised by specific prescribing information

g If relapse treatment requires high-dose steroid therapy

h Information current as of February 11, 2021

i NMSS guidance on timing of medications [80]: S1P receptor modulators: consider getting fully vaccinated (defined as 2 doses of the mRNA [Pfizer BioNTech or Moderna] or 1 dose of the vector vaccine [Janssen]) ≥ 2–4 weeks before starting. If already on an S1P receptor modulator, continue medication and get vaccinated when a vaccine is available. Alemtuzumab: consider getting fully vaccinated ≥ 4 weeks before starting. If already on alemtuzumab, wait ≥ 24 weeks after the last dose of alemtuzumab before getting vaccinated. If due for next treatment course, when possible, resume alemtuzumab ≥ 4 weeks or more after getting fully vaccinated. Cladribine: consider getting fully vaccinated ≥ 2–4 weeks before starting. If due for the next cladribine treatment, resume cladribine 2–4 weeks after getting fully vaccinated. Ocrelizumab/rituximab: consider getting fully vaccinated ≥ 2–4 weeks before starting treatment. If already on ocrelizumab or rituximab, consider getting fully vaccinated ≥ 12 weeks after the last dose. When possible, resume ocrelizumab or rituximab ≥ 4 weeks after getting fully vaccinated. Ofatumumab: consider getting fully vaccinated ≥ 2–4 weeks before starting treatment. If already on ofatumumab, when possible resume ofatumumab 2–4 weeks after getting fully vaccinated. High-dose steroids: consider getting the vaccine injection(s) 3–5 days after the last dose

If relapse treatment requires high-dose steroid therapy

Information current as of February 11, 2021

NMSS guidance on timing of medications [80]: S1P receptor modulators: consider getting fully vaccinated (defined as 2 doses of the mRNA [Pfizer BioNTech or Moderna] or 1 dose of the vector vaccine [Janssen]) ≥ 2–4 weeks before starting. If already on an S1P receptor modulator, continue medication and get vaccinated when a vaccine is available. Alemtuzumab: consider getting fully vaccinated ≥ 4 weeks before starting. If already on alemtuzumab, wait ≥ 24 weeks after the last dose of alemtuzumab before getting vaccinated. If due for next treatment course, when possible, resume alemtuzumab ≥ 4 weeks or more after getting fully vaccinated. Cladribine: consider getting fully vaccinated ≥ 2–4 weeks before starting. If due for the next cladribine treatment, resume cladribine 2–4 weeks after getting fully vaccinated. Ocrelizumab/rituximab: consider getting fully vaccinated ≥ 2–4 weeks before starting treatment. If already on ocrelizumab or rituximab, consider getting fully vaccinated ≥ 12 weeks after the last dose. When possible, resume ocrelizumab or rituximab ≥ 4 weeks after getting fully vaccinated. Ofatumumab: consider getting fully vaccinated ≥ 2–4 weeks before starting treatment. If already on ofatumumab, when possible resume ofatumumab 2–4 weeks after getting fully vaccinated. High-dose steroids: consider getting the vaccine injection(s) 3–5 days after the last dose

---

△ Adis
recently advised vaccination for most people with MS, which can occur while treatment with DMTs is ongoing [14, 19, 79]. Both have also recently made recommendations regarding the timing of DMTs with COVID-19 vaccination (Table 2) [19, 80].

These COVID-19 vaccination guidance and guidelines are living documents based on what has been learned from previous vaccine studies, DMT prescribing information, ongoing studies and registries such as the COViMS registry, and expert consensus, and will be updated over time as more data become available and as more vaccines are approved for use.

**VACCINE EFFICACY AND DMTS**

Because DMTs have immunosuppressive and/or immunomodulating effects, data on vaccination efficacy in people with MS treated with DMTs may help inform how the immune response may be impacted and whether there should be considerations about optimal timing of vaccine administration with DMTs. Most reports have been on the response to influenza vaccination. People with MS are able to mount a cellular immune response following influenza vaccination [83]. However, increases in influenza-specific T cells following vaccination are higher in people with MS than in healthy controls and, importantly, no increases in T cell responses to central nervous system myelin proteins (i.e., human myelin basic protein or recombinant human myelin oligodendrocyte protein) were seen [83]. A meta-analysis of studies on influenza vaccination in patients with MS found no statistical difference in immune responses versus healthy controls and that most immunotherapies did not affect the immune response [84].

As previously mentioned, the different mechanisms of action for DMTs (summarized in Table 3) have been shown to impact immune responses to vaccination with administration of different DMTs. This has been demonstrated in clinical studies, case reports, and some preclinical data (Table 4). Several reports on interferon beta products indicate that people with MS treated with interferon beta can generate protective levels of response to influenza, tetanus-diphtheria toxoid, pneumococcal vaccine polyvalent, and meningococcal vaccines [85–90], with no evidence for a reduction in tetanus toxoid-induced T cell responses [91]. Endogenous interferon betas are part of the type I interferon family, which play an important role in antiviral response [92, 93]. The binding of interferons to their receptors causes a signaling cascade leading to upregulation of genes that results in production of antiviral molecules such as myxovirus resistance proteins, adenosine deaminase acting on RNA (ADAR1), oligoadenylate synthetase, and RNase L nuclease [93–96]. Postmarketing surveillance data showing no increased risk of infection suggest therapeutic interferon betas may have some protective antiviral effects [97].

For all other DMTs, data suggest a diminished immune response to vaccination, usually influenza vaccination. Glatiramer acetate may also impact the immune response, though most studies indicate adequate responses [87, 130, 131]; in one study, patients on glatiramer acetate had slightly lower responses to influenza vaccination compared with healthy controls [90]. Teriflunomide was found to cause a mild dose-dependent reduction in the efficacy of influenza and rabies vaccines [86, 134]; higher doses of teriflunomide induced a lower response to at least one strain of influenza in the vaccines [86]. Among sphingosine-1-phosphate (S1P) receptor modulators, most data were available for fingolimod. Patients treated with fingolimod had reduced response rates to influenza vaccination versus patients treated with interferon or placebo or versus healthy controls and no increase in avidity (binding) of influenza-specific immunoglobulin (Ig) G was seen [87, 130, 136, 137]. Studies and case reports also indicate that fingolimod affected responses to varicella zoster and pneumococcal polysaccharide vaccines [138–141]. The few data available for the other S1P receptor modulators, including a pooled analysis of two trials of ozanimod (n = 2659), suggest similar reductions in responses to vaccination [145, 146].

A study on dimethyl fumarate found adequate seroprotection and no reduction in
Table 3 DMTs and vaccination recommendations for people with MS

| DMT category           | Proposed mechanism of action                                                                 | Vaccine recommendations from USPI                                      |
|------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Interferons [98–102]   |                                                                                               |                                                                        |
| Interferon beta-1b     | Unknown, but hypotheses include [103, 104]                                                       | No vaccine-specific language                                           |
| (Betaseron®)           | Promote shift from Th1 to Th2                                                                 |                                                                        |
| Interferon beta-1b     | Reduce trafficking across blood–brain barrier                                                  |                                                                        |
| (Extavia®)             | Restore T<sub>reg</sub> function                                                               |                                                                        |
| Interferon beta-1a     | Inhibit antigen presentation                                                                  |                                                                        |
| SC (Rebif®)            | Enhance apoptosis of autoreactive T cells                                                       |                                                                        |
| Interferon beta-1a     |                                                                                               |                                                                        |
| IM (Avonex®)           |                                                                                               |                                                                        |
| Peginterferon beta-1a  |                                                                                               |                                                                        |
| (Plegridy®)            |                                                                                               |                                                                        |
| Glatiramer acetate     | Not fully understood, but hypotheses include [103, 106]                                        | No vaccine-specific language                                           |
| [105]                  | Promote differentiation in Th2 and T<sub>reg</sub> cells, leading to bystander suppression in the central nervous system |                                                                        |
|                       | Increase release of neurotrophic factors from immune cells                                      |                                                                        |
|                       | Cause deletion of myelin-reactive T cells                                                      |                                                                        |
|                       | May inhibit Th17 immune response by direct influence on T cells [107]                          |                                                                        |
| DHODH inhibitor        |                                                                                               |                                                                        |
| Teriflunomide [108]    | Unknown; has been shown to [109]                                                               |                                                                        |
|                       | Has a cytostatic effect on rapidly dividing T and B lymphocytes in the periphery               |                                                                        |
|                       | Inhibits de novo pyrimidine synthesis                                                         |                                                                        |
|                       |                                                                                               | No clinical data on the efficacy/safety of live vaccinations in patients taking teriflunomide |
|                       |                                                                                               | Live vaccines are not recommended                                      |
|                       |                                                                                               | Long half-life needs to be taken into consideration after stopping treatment and before administration of a live vaccine |
|                       |                                                                                               | Advise patients that use of some vaccines should be avoided during treatment with teriflunomide and for 6 months after stopping treatment |
Table 3 continued

| DMT category     | Proposed mechanism of action                                                                                                                                      | Vaccine recommendations from USPI                                                                 |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| SIP receptor modulators |                                                                                                                                                                 |                                                                                                   |
| Fingolimod [110] | Unknown, but Active metabolite binds with high affinity to SIP receptor on lymphocytes, thus preventing their egress from lymph organs [111, 112] Increases CD39-expressing Treg cells and decreases B cells and CD4^+ cells [113] | Patients without confirmed history of chicken pox or documentation of full course of vaccination against VZV should be tested for VZV Abs before starting treatment. VZV vaccination is recommended in VZV Ab-negative patients before starting treatment, and initiation of fingolimod treatment should be delayed for 1 month to allow full effect of vaccination to take effect. Vaccination against HPV should be considered before initiating treatment, taking into account vaccine recommendations. Reduces immune response to vaccination, based on results from 2 placebo-controlled studies. Vaccination may be less effective during and for up to 2 months after discontinuation of treatment. Avoid use of live attenuated vaccines during and for 2 months after treatment because of the risk of infection. Pediatric patients should complete all immunizations in accordance with current immunization guidelines before initiating treatment. Vaccinations may be less effective if administered during treatment. Treatment discontinuation 1 week before and until 4 weeks after a planned vaccination is recommended. |
| Siponimod [114]  | Unknown, but binds SIP receptors 1 and 5 with high affinity, blocking lymphocyte egress from lymph nodes                                                                 | Avoid use of live attenuated vaccines during treatment and for 4 weeks after stopping treatment because of the risk of infection. Before initiating treatment, patients should be tested for VZV Ab; VZV vaccination is recommended in VZV Ab-negative patients before starting treatment. Patients without an HCP-confirmed history of chicken pox or documentation of a full course of vaccination against VZV should be tested for VZV Ab before initiating treatment. A full course of vaccination with varicella vaccine is recommended for Ab-negative patients before starting treatment; initiation of treatment should be postponed for 4 weeks to allow the full effect of vaccination to occur. Vaccinations may be less effective if administered during treatment. Vaccinations may be less effective during and for up to 1 month after discontinuation of treatment. Treatment discontinuation 1 week before and until 4 weeks after a planned vaccination is recommended. |
| DMT category | Proposed mechanism of action | Vaccine recommendations from USPI |
|--------------|-----------------------------|----------------------------------|
| Ozanimod [115] | Unknown, but binds with high affinity to S1P receptors 1 and 5, thereby blocking lymphocyte egress from lymph nodes and reducing the number of lymphocytes in peripheral blood | Avoid use of live attenuated vaccines during and for 3 months after treatment. If live attenuated vaccine immunizations are required, administer ≥ 1 month prior to initiation treatment. Patients without an HCP-confirmed history of chicken pox or documentation of a full course of vaccination against VZV should be tested for VZV Ab before initiating treatment. A full course of vaccination with varicella vaccine is recommended for Ab-negative patients before starting treatment; initiation of treatment should be postponed for 4 weeks to allow the full effect of vaccination to occur. No clinical data available on the efficacy or safety of vaccinations in patients taking ozanimod. Vaccinations may be less effective if administered during treatment. Vaccinations may be less effective during and for up to 3 months after discontinuation of treatment. Live attenuated vaccines may carry the risk of infection and should therefore be avoided during treatment and for up to 3 months after discontinuation of treatment. |
| Ponesimod [116] | Unknown but binds with high affinity to S1P receptor 1, thereby blocking the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood | Patients without a healthcare professional confirmed history of chicken pox or without documentation of a full course of vaccination against VZV should be tested for antibodies to VZV before initiating ponesimod treatment. A full course of vaccination for Ab-negative patients with varicella vaccine is recommended prior to commencing treatment with ponesimod, following which initiation of treatment with ponesimod should be postponed for 4 weeks to allow the full effect of vaccination to occur. No clinical data are available on the efficacy and safety of vaccinations in patients taking ponesimod. Vaccinations may be less effective if administered during ponesimod treatment. If live attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of ponesimod. Avoid the use of live attenuated vaccines during and for 1–2 weeks after treatment with ponesimod. During, and for up to 1–2 weeks after discontinuation of, treatment with ponesimod, vaccinations may be less effective. The use of live attenuated vaccines may carry the risk of infection and should therefore be avoided during ponesimod treatment and for 1–2 weeks after discontinuation of treatment with ponesimod. |
| DMT category | Proposed mechanism of action | Vaccine recommendations from USPI |
|--------------|-----------------------------|----------------------------------|
| Fumarates    |                             |                                  |
| Dimethyl fumarate (DMF) [117] | Unknown; thought to promote anti-inflammatory and cytoprotective activities mediated by the Nrf2 pathway [118] | Concomitant exposure to DMF did not attenuate Ab responses to tetanus toxoid-containing vaccine, pneumococcal polysaccharide, or meningococcal vaccines relative to Ab responses in patients treated with nonpegylated interferon in a randomized, open-label study in adults with relapsing forms of MS. The impact of these findings on vaccine effectiveness in this patient population is unknown. Safety and effectiveness of concomitant administration of live and live attenuated vaccines have not been assessed. |
| Diroximel fumarate [119] | Unknown; thought to promote anti-inflammatory and cytoprotective activities mediated by Nrf2 pathway, which is involved in cellular response to oxidative stress [USPI] | A randomized, open-label study examined the concomitant use of DMF (which has the same active metabolite as diroximel fumarate) and several nonlive vaccines in adults 27–55 years of age with relapsing forms of MS (38 subjects undergoing treatment with DMF at the time of vaccination and 33 subjects undergoing treatment with non-pegylated interferon at the time of vaccination). Concomitant exposure to DMF did not attenuate Ab responses to tetanus toxoid-containing vaccine, pneumococcal polysaccharide, and meningococcal vaccines relative to Ab responses in interferon-treated patients. The impact of these findings on vaccine effectiveness in this patient population is unknown. The safety and effectiveness of live or live-attenuated vaccines administered concomitantly with diroximel fumarate or DMF have not been assessed. |
| Monomethyl fumarate [120] | Unknown; activates Nrf2 pathway, which is involved in cellular response to oxidative stress [USPI] | No vaccine-specific language |
| High-efficacy DMTs Anti-VLA4 | | |
| Natalizumab [121] | Blocks α4 subunit of α4β1 and α4β7 integrins on lymphocytes, thus reducing trafficking of lymphocytes into the central nervous system [122] | No data are available on the effects of vaccination in patients receiving natalizumab. No data are available on the secondary transmission of infection by live vaccines in patients receiving natalizumab. |
| DMT category | Proposed mechanism of action | Vaccine recommendations from USPI |
|--------------|-----------------------------|----------------------------------|
| Anti-CD20    | Ocrelizumab [123] Unknown but thought to bind CD20, a cell surface antigen, on pre-B and mature B lymphocytes, causing Ab-dependent and complement-mediated cytolysis | Vaccination with live attenuated or live vaccines not recommended during treatment and after discontinuation until B cell repletion. Administer all immunizations according to immunization guidelines ≥ 4 weeks before starting treatment for live or live attenuated vaccines and, whenever possible, ≥ 2 weeks before starting treatment for nonlive vaccines. Ocrelizumab may interfere with the effectiveness of nonlive vaccines. The safety of immunization with live or live attenuated vaccines following treatment has not been studied. Confirm recovery of B cell counts, as measured by CD19⁺ B cells, in infants born to mothers exposed to ocrelizumab during pregnancy before administering live or live attenuated vaccines to infants. Depletion of B cells in these infants may increase the risks from live or live attenuated vaccines. Inactivated vaccines may be administered before recovery of B cell depletion, but vaccine immune responses should be evaluated in consultation with a qualified specialist to ensure protective immune response was mounted. Concomitant exposure to ocrelizumab attenuated Ab responses to tetanus toxoid-containing vaccine, pneumococcal polysaccharide, pneumococcal conjugate vaccines, and seasonal inactivated influenza vaccines in a phase 3b, open-label study of ocrelizumab vs no treatment in adults with relapsing forms of MS. The impact of the observed attenuation on vaccine effectiveness in this patient population is unknown. The safety and effectiveness of live or live attenuated vaccines administered concomitantly with ocrelizumab have not been assessed. The potential duration of B cell depletion in infants following maternal exposure to ocrelizumab has not been evaluated in clinical trials, and the impact of B cell depletion on vaccine safety and effectiveness is unknown. |
| DMT category | Proposed mechanism of action | Vaccine recommendations from USPI |
|--------------|-----------------------------|----------------------------------|
| Ofatumumab   | Unknown, but presumed to involve binding to CD20, a cell surface antigen on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in Ab-dependent cellular cytolysis and complement-mediated lysis | Live attenuated or live vaccines not recommended during treatment and after discontinuation, until B cell repletion. The safety of immunization with live or live attenuated vaccines following ofatumumab treatment has not been studied. All immunizations should be administered according to immunization guidelines ≥ 4 weeks before starting treatment for live or live attenuated vaccines and, when possible, ≥ 2 weeks before starting treatment for inactivated vaccines. Ofatumumab may interfere with effectiveness of inactivated vaccines. Confirm recovery of B cell counts in infants born to mothers treated with ofatumumab during pregnancy before administering live or live attenuated vaccines to infants. Inactivated vaccines may be administered before recovery of B cell depletion, but vaccine immune responses should be evaluated. |
| Rituximab    | Targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes. Upon binding to CD20, rituximab mediates B cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity and Ab-dependent cell-mediated cytotoxicity | The safety of immunization with live viral vaccines following rituximab therapy has not been studied, and vaccination with live virus vaccines is not recommended before or during treatment. Patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating rituximab, and administered nonlive vaccines at least 4 weeks prior to a course of rituximab. |
| Alemtuzumab  | Unknown, but presumed to involve binding to CD52, a cell surface antigen on T and B lymphocytes, and on natural killer cells, monocytes, and macrophages. This results in depletion of T and B lymphocytes after infusion. | Do not administer live viral vaccines following a course of alemtuzumab. Patients treated with alemtuzumab have altered immunity and may be at increased risk of infection following administration of live viral vaccines. Patients without confirmed history of VZV or documentation of VZV vaccination should be tested for VZV Abs before starting treatment. VZV vaccination is recommended in VZV Ab-negative patients before starting treatment; postpone starting treatment until ≥ 6 weeks after vaccination. Patients should complete any necessary immunizations ≥ 6 weeks before starting treatment. |
Table 3 continued

| DMT category                  | Proposed mechanism of action                                                                 | Vaccine recommendations from USPI                                                                                                                                 |
|-------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DNA synthesis disrupters      | Cladribine [128] Thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes | Vaccination of patients who are Ab-negative for VZV recommended before starting treatment                                                                                                              |
|                               |                                                                                                | Administer all immunizations according to immunization guidelines before starting treatment                                                                                                        |
|                               |                                                                                                | Administer live attenuated or live vaccines ≥ 4–6 weeks before starting treatment, because of a risk of active vaccine infection                                                                 |
|                               |                                                                                                | Avoid vaccination with live attenuated or live vaccines during and after treatment while the patient’s white blood cell counts are not within normal limits                                             |
| Mitoxantrone [129]            | Intercalates into DNA through hydrogen bonding, causing cross-links and strand breaks          | No vaccine-specific language                                                                                                                                                                 |
|                               | Interferes with RNA                                                                             |                                                                                                                                                                                                 |
|                               | Inhibits topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA       |                                                                                                                                                                                                 |
|                               | Inhibits B cell, T cell, and macrophage proliferation in vitro and impairs antigen presentation and secretion of interferon gamma, tumor necrosis factor alpha, and interleukin-2 |                                                                                                                                                                                                 |

Ab antibody, CD cluster of differentiation, DHODH dihydroorotate dehydrogenase, DMT disease-modifying therapy, HCP healthcare provider, HPV human papillomavirus, MS multiple sclerosis, S1P sphingosine-1-phosphate, Th1/2 type 1/2 helper T cells, Th17 T helper 17 cell, Treg regulatory T cell, USPI United States prescribing information, VLA4 very late antigen 4, VZV varicella zoster virus

* The EU label states there was no significant difference in the humoral immune response to a recall antigen (tetanus toxoid) and only slightly slower and reduced humoral immune response to a neoantigen (keyhole limpet hemocyanin) in patients treated with natalizumab for 6 months compared with an untreated control group. Live vaccines have not been studied.
Table 4  Studies on effect of DMTs on response to vaccination

| DMT                  | Study groups | Vaccine                          | Outcome                                                                 | AEs                                           |
|----------------------|--------------|----------------------------------|-------------------------------------------------------------------------|-----------------------------------------------|
| IFN                  |              |                                  |                                                                         |                                               |
| IFN beta-1b (Betaseron<sup>®</sup>) | IFN beta-1, N = 46 | 2011/2012 influenza               | > 90% achieved antibody titters ≥ 40 for all strains [86]               | Injection site pain (n = 3)                    |
|                      | IFN, N = 45  | 2010/2011 and 2011/2012 influenza | > 84% seroprotection rate [87]                                         | Flu-like symptoms (n = 4); headache           |
|                      | IFN beta-1b (Extavia<sup>®</sup>) | IFN beta, n = 26                  | Comparable frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG [88] | Not studied                                   |
| IFN beta-1a SC (Rebif<sup>®</sup>) | IFN beta-1a, n = 86 | 2008/2009 and 2009/2010 influenza |                                                                         |                                               |
| IFN beta-1a IM (Avonex<sup>®</sup>) | No IFN beta-1a, n = 77 | 2002/2003 influenza               | No difference in antibody titer response [89]                           | Not studied                                   |
| PegIFN beta-1a (Pegridy<sup>®</sup>) | IFN beta, n = 36 | 2009 swine flu (H1N1)             | Similar protection rates [90]                                           | 7.9% and 7.8% MS exacerbations with 2009 and 2010 vaccine |
|                      | HCs, n = 216 | 2010 influenza                    |                                                                         |                                               |
|                      | IFN beta, n = 17 |                                        |                                                                         |                                               |
|                      | HCs, n = 73  | 2012/2013 influenza               | Comparable protection rates against H1N1 at 3, 6, and 12 months [130]  | Not studied                                   |
|                      | IFN beta-1a/1b, n = 25 |                                        |                                                                         |                                               |
|                      | HCs, n = 53  | 2012/2013 influenza               |                                                                         |                                               |
| Nonpegylated IFN, n = 33 | TT-containing |                                        | Similar antibody responses [85]                                         | Vaccination-emergent AEs in 55%, nonpegylated IFN; 42%, DMF |
| DMF, n = 38          | Pneumococcal polysaccharide |                                    |                                                                         |                                               |
|                      | Meningococcal |                                    |                                                                         |                                               |
| IFN beta, n = 10     | Tick-borne encephalitis |                                        | Increased antibody titer in 9 [131]                                     | Local side effects (pain, induration) but DMT not specified |
| IFN beta, N = 14     | TT           |                                    | Reduced IFN-gamma and IL-4 responses to TT; no change in               | Not studied                                   |
|                      |              |                                    | TT-induced CD4<sup>+</sup> T cell proliferation [91]                   |                                               |
| High titer IFN alpha/beta, mouse model | Influenza |                                    | Th1 type of immune response and protection against virus                | Not applicable                                |
|                      |              |                                    | challenge [132]                                                         |                                               |
| IFN beta, mouse model | Recombinant vaccinia viruses followed by fowlpox virus recombinants at 2-week intervals |                                    | Robust anti-HA CD8<sup>+</sup> T cell response [133]                     | Not applicable                                |
| DMT                | Study groups¹ | Vaccine       | Outcome                                                                 | AEs                                                                 |
|--------------------|---------------|---------------|------------------------------------------------------------------------|----------------------------------------------------------------------|
| **Glatiramer acetates** |               |               |                                                                        |                                                                      |
| Copaxone⁸          |               |               |                                                                        |                                                                      |
| Glatiramer acetate, n = 37 | 2009 swine flu (H1N1) | Reduced response in glatiramer acetate group (21.6% vs 43.5%) [90] | Not studied                                                          |
| HCs, n = 216       |               |               |                                                                        |                                                                      |
| Glatiramer acetate, n = 12 | 2010 influenza | Reduced response in glatiramer acetate group (58.3% vs 71.2% H1N1; 41.7% vs 79.5% H3N2) [90] | Not studied                                                          |
| HCs, n = 73        |               |               |                                                                        |                                                                      |
| Glatiramer acetate, n = 23 | 2012/2013 influenza | Similar protection rates against H1N1 at 3, 6, and 12 months [130] | Not studied                                                          |
| HCs, n = 53        |               |               |                                                                        |                                                                      |
| Glatiramer acetate, n = 26 | 2010/2011 and 2011/2012 influenza | > 73.1% seroprotection rate to 3 different strains [87] | Flu-like symptoms (n = 3); temperature increase (n = 2); nightly sweating (n = 1) |
| HCs, n = 53        |               |               |                                                                        |                                                                      |
| Glatiramer acetate, n = 5 | Tick-borne encephalitis | 3 had protective titers before vaccination and developed 2- to 9.6-fold increases in antibody titers [131] | Local side effects (pain, induration); DMT not specified            |
|                   |               |               |                                                                        |                                                                      |
| **DHODH inhibitor** |               |               |                                                                        |                                                                      |
| Teriflunomide      |               |               |                                                                        |                                                                      |
| Teriflunomide, 7 mg, n = 41 | 2011/2012 influenza | > 70% achieved antibody titers ≥ 40 for all strains; seroprotection to H3N2 was lower with 14 mg dose [86] | Injection site pain, n = 1 in each group                             |
| 14 mg, n = 41      |               |               |                                                                        |                                                                      |
| Teriflunomide, n = 23 | Rabies        | Lower antibody titers in teriflunomide group; no adverse impact on recall antigen response [134] | Treatment-emergent AEs: teriflunomide, 17.4%; placebo, 30.4%         |
| HCs placebo, n = 23 |               |               |                                                                        |                                                                      |
| **SIP receptor modulators** |               |               |                                                                        |                                                                      |
| Fingolimod        |               |               |                                                                        |                                                                      |
| Fingolimod, n = 14 | 2008/2009 and 2009/2010 influenza | Cellular and humoral immune responses similar to controls [135] | Not studied                                                          |
| HCs, n = 18        |               |               |                                                                        |                                                                      |
| Fingolimod, n = 95 | 2010/2011 influenza | Fingolimod group had lower immune responses [136] | No new safety or tolerability signals                                |
| Placebo, n = 43    |               |               |                                                                        |                                                                      |

¹ HCs = healthy controls; AEs = adverse events; DMT = disease-modifying therapies; TT = tetanus toxoid; *= study group size not specified
| DMT | Study groups | Vaccine | Outcome | AEs |
|-----|--------------|---------|---------|-----|
| Fingolimod, \( n = 10 \) | Influenza | Fingolimod group had no increases in avidity (binding) of influenza-specific IgG vs IFN beta or control \([137]\) | Comparable tolerability across groups |
| IFN beta, \( n = 10 \) | | | |
| HCs, \( n = 15 \) | | | |
| Fingolimod, \( n = 6 \) | 2010/2011 and 2011/2012 influenza | Low protective antibody titer to H3N2 \([87]\) | Exanthema, \( n = 2 \) |
| Fingolimod, \( n = 15 \) | 2012/2013 influenza | Lower protection rates were seen in fingolimod group at 3, 6, and 12 months \([130]\) | Not studied |
| HCs, \( n = 53 \) | | | |
| Fingolimod, \( n = 11 \) | VZV | 7/11 patients had lower IgG-VZV antibody levels 2.4 years after starting fingolimod \([138]\) | 3/7 patients stopped treatment because of an AE |
| Fingolimod, \( n = 2 \) | Tick-borne encephalitis | Lowest increase in antibody titer compared with other DMTs \([131]\) | Local side effects (pain, induration) but DMT not specified |
| Fingolimod, \( n = 48 \) | KLH | Mild to moderate decreases in anti-KLH and anti-PPV-23 IgG and IgM levels, indicating mild to moderate decrease in humoral and cellular immune responses to neoantigens; no effect on recall antigen (TT) response \([139]\) | Most common AEs: headache, injection site pain, and dizziness, which occurred across all treatment groups |
| HCs placebo, \( n = 24 \) | Pneumococcal polysaccharide (PPV-23) | Response to vaccination diminished \([140]\) | Patient infected daughter with chicken pox and had 2 bouts of shingles |
| Fingolimod, 1 patient with MS and childhood history of chicken pox [case report] | VZV | Developed VZV encephalitis after 6 months of fingolimod and 5 days of high-dose systemic corticosteroids \([141]\) | Not applicable |
| Fingolimod, 1 patient with MS and chicken pox as a child [case report] | VZV (shingles vaccine 6 months before initiating fingolimod) | | |
| Fingolimod | BCG | Reduced protection against TB infection; administration during infectious challenge did not. Suggests memory T lymphocytes that migrate to the lung following vaccination are sufficient for protection \([142]\) | Not applicable |
| Mouse model | Ovalbumin plus CpG oligodeoxynucleotide adjuvant; priming via nasal route | Greater buildup of more extensively divided T cells within draining lymph nodes; in distal lymph nodes percentage of divided transgenic cells was mostly reduced \([143]\) | Not applicable |
| DMT              | Study groups*                          | Vaccine                                | Outcome                                                                 | AEs                                                                 |
|------------------|----------------------------------------|----------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------|
| Fingolimod      | Mouse model                            | Influenza A                            | Protected against TB by CD4+ memory T cells [144]                      | Not applicable                                                      |
| Siponimod       | Siponimod, n = 90 across 3 groups of HCs | Pneumococcal polysaccharide (PPV-23)   | No effect on PPV-23 antibody response. Response criteria were also met for influenza, but lower titers at time of vaccination [145] | Similar incidence of AEs between siponimod and placebo              |
| Ozanimod        | Ozanimod, n = 2659 with positive VZV IgG antibody status or VZV vaccination 30+ days before randomization | VZV                                    | 5 (0.6%) VZV cases reported with ozanimod 1 mg and 3 (0.3%) with ozanimod 0.5 mg [146] | No patient discontinued treatment because of VZV                   |
| Fumarates       | Dimethyl fumarate (DMF), n = 38         | TT-containing                          | Concomitant exposure to DMF did not diminish antibody responses versus antibody responses in patients treated with nonpegylated IFN [85] | Vaccination-emergent AEs occurred in 42% with DMF and in 55% with nonpegylated IFN |
|                 | Nonpegulated IFN, n = 33                | Pneumococcal polysaccharide            |                                                                         |                                                                     |
|                 |                                        | Meningococcal                          |                                                                         |                                                                     |
| High-efficacy DMTs |                                         |                                        |                                                                         |                                                                     |
| Anti-VLA4        |                                        |                                        |                                                                         |                                                                     |
| DMT         | Study groups<sup>a</sup> | Vaccine | Outcome                                                                                                                                   | AEs                                                                 |
|-------------|---------------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Natalizumab | Natalizumab, n = 30      | TT      | Protective levels of anti-TT IgG antibodies achieved and demonstrated primary immunization responses to a neoantigen [147]               | No unexpected events observed                                       |
|             | Neoantigen (KLH)          |         |                                                                                                                                         |                                                                     |
|             | Natalizumab, n = 17      | Influenza A (H1N1/A-H3N2/B) | Significant increases in anti-influenza B IgG following influenza A and B vaccination; humoral response was comparable to HCs [148]       | Not studied                                                        |
| HCs, n = 10 |                            |         |                                                                                                                                         |                                                                     |
|             | Natalizumab, n = 17      | 2009 swine flu (H1N1) | Reduced (23.5%) response compared with HCs (43.5%) [90]                                                                               | Not studied                                                        |
| HCs, n = 216|                            |         |                                                                                                                                         |                                                                     |
|             | Natalizumab, n = 8       | 2010 influenza (including H1N1, H3N2, and B strains) | H1N1 protection: natalizumab, 75.0%; controls, 71.2%                                                                               | Not studied                                                        |
| HCs, n = 73 |                            |         | H3N2 protection: natalizumab, 50.0%; controls, 79.5% [90]                                                                               |                                                                     |
|             |                           |         | Note: limited sample size and no adjustment for disease factors                                                                       |                                                                     |
|             | Natalizumab, n = 12      | 2012/2013 influenza | Reduced response at 3 and 6 months post vaccination; comparable response to HCs at 12 months [130]                                     | Not studied                                                        |
| HCs, n = 53 |                            |         |                                                                                                                                         |                                                                     |
|             | Natalizumab, n = 14      | 2010/2011 and 2011/2012 influenza | Low response rates (14.3% seroprotection, all strains) [87]                                                                            | Not studied                                                        |
| Anti-CD20   |                           |         | Note: small sample size is a limitation of this study                                                                               |                                                                     |
| Anti-CD20   | Ocrelizumab, n = 68 [patients with MS] | TT      | Reduced response compared with controls [149]                                                                                           | No new safety signals                                              |
|             | HCs, n = 34               | Pneumococcal |                                                                                                                                         |                                                                     |
|             |                           | KLH     |                                                                                                                                         |                                                                     |
|             |                           | Influenza |                                                                                                                                         |                                                                     |
|             | Patient with MS who received VZV vaccine 4 months before first dose of ocrelizumab [case report], n = 1 | VZV     | VZV IgG negative 5 months later; remained VZV IgG negative despite additional varicella vaccination [150]                               | Not applicable                                                     |
| Anti-CD52   | Alemtuzumab, n = 24      | Pneumococcal polysaccharide | Humoral response was normal, but when vaccination occurred ≤ 6 months after treatment, smaller proportions responded (2/5 vs 12/15 vaccinated > 6 months after alemtuzumab) [151] | Not studied                                                        |
|             |                            | Diphtheria, TT, and poliomyelitis |                                                                                                                                         |                                                                     |
|             |                            | HiB and meningococcal group C |                                                                                                                                         |                                                                     |
immune responses to tetanus toxoid, pneumococcal polysaccharide, or meningococcal vaccines compared with interferon [85]. In addition, in the 96-week PROCLAIM study, antibody (IgA, IgG, IgM, and IgG1–4) subclass levels were stable with long-term (96-week) dimethyl fumarate treatment, though lymphocyte levels decreased (i.e., naïve CD4+ and CD8+ T cell increases, CD4+ and CD8+ central and effector memory T cell decreases) [152]. This indicated a shift from an inflammatory to an anti-inflammatory cell profile without impairment of humoral immunity [152]. No data were available for the other fumarates.

Some information was available for several high-efficacy DMTs in people with MS. A randomized controlled study in patients with MS treated with natalizumab showed that all evaluated patients achieved protective levels of anti-tetanus toxin IgG antibodies, and a slightly lower proportion of responders to primary immunization with keyhole limpet hemocyanin with natalizumab compared to control group, suggesting that natalizumab may not significantly influence responses to primary or secondary immunization [147]. In several small studies, patients with MS treated with natalizumab achieved either comparable or lower responses to influenza vaccination versus those treated with interferons or versus healthy controls depending on the strain [87, 90, 130]. Although the studies were limited by small sample sizes with no adjustment for disease factors in the patients with MS, the responses were generally considered more than adequate to achieve seroprotection.

In a large study in patients with MS (N = 102), those treated with ocrelizumab were found to have substantially impaired responses to tetanus toxoid, influenza, and pneumococcal vaccines and to the neoantigen keyhole limpet hemocyanin compared with controls on interferon beta or no DMT [149]. Despite these attenuated immune responses, patients still mounted a humoral response, and the authors concluded that an adequate vaccine response is generated after ocrelizumab treatment that is seroprotective [149]. On the basis of these data, there may be an optimal timing of vaccine administration with this DMT. In phase 3 trials,
| Vaccine               | Description                                                                 | Administration                  | Efficacy (primary endpoint) | Safety                                                                                   |
|----------------------|------------------------------------------------------------------------------|---------------------------------|------------------------------|------------------------------------------------------------------------------------------|
| BNT162b2 (Pfizer/BioNTech) | LNP-encapsulated mRNA encoding SARS-CoV-2 spike protein modified by 2 proline mutations [168] | Two 30-μg doses, 21 days apart [169, 171] | 95.0% efficacy ≥ 7 days after dose 2 (N = 36,523); COVID-19 illness occurred in 162/18,325 with placebo vs 8/18,198 with BNT162b2 [171] | Adverse events reported 7 days after dose 2 of BNT162b2 (N = 21,813) |
| mRNA-1273 (Moderna)  | LNP-encapsulated mRNA encoding SARS-CoV-2 spike protein altered by 2 proline substitutions [53] | Two 100-μg doses, 28 days apart [169, 170] | 94.1% efficacy (p < 0.001) at 14 days after dose 2 (N = 28,207); COVID-19 illness occurred in 185/14,073 with placebo vs 11/14,134 with mRNA-1273 [170] | Solicited adverse reactions (grade 3) reported 7 days after dose 2 of mRNA-1273 (N = 14,677) |

Local: pain (78% in 16–55-year-olds; 66% in > 55-year-olds), redness (6%, 7%), and swelling (6%, 7%) Systemic: fever (16%, 11%), fatigue (59%, 51%), headache (52%, 39%), chills (35%, 23%), vomiting (2%, 1%), diarrhea (10%, 8%), muscle pain (37%, 29%), joint pain (22%, 19%), use of antipyretic medication (45%, 38%) Serious events in 0.6% and lymphadenopathy in 0.3% reported at any time (N = 21,621) |

Local: pain (4.1%), erythema (2.0%), swelling (1.7%), axillary swelling/tenderness (0.5%) Systemic (grade 3/4): fever (1.4%/ < 0.1%), headache (4.5%/0%), fatigue (9.7%/0%), myalgia (9.0%/0%), arthralgia (5.2%/ 0%), nausea/vomiting (0.1%/ < 0.1%), chills (1.3%/0%) Bell's palsy in 3 vaccine recipients > 28 days after injection
| Vaccine            | Description                                                                 | Administration                                      | Efficacy (primary endpoint)                                                                 | Safety                                                                 |
|--------------------|------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Ad26.COV2.S        | Recombinant replication-deficient adenovirus vector vaccine                  | One 0.5-mL dose, 5 × 10¹⁰ vp                          | 66.9% efficacy at 14 days after administration (N = 39,321⁵⁹) [59]: COVID-19 illness    | Solicited AEs (grade 3) up to 28 days after administration of Ad26.COV2.S (N = 3356⁶⁰⁵⁹) [59]: erythema (0.2%), pain (0.3%), swelling (0.2%), fatigue (0.1%), headache (0.7%), myalgia (1.0%), nausea (0.2%), pyrexia (0.2%); no grade 4 solicited AEs |
| (VAC31518; JNJ-78436735; Janssen Biotech) | encoding SARS-CoV-2 spike protein gene altered by 2 proline substitutions [58, 59] |                                                      | (PCR⁺: moderate to severe/critical) in 348/19,544 with placebo vs 116/19,514 with Ad26.COV2.S | Serious AEs of special interest/related to vaccine: facial paralysis (n = 2), brachial radiculitis (n = 1), Guillain–Barré syndrome (n = 1), transverse sinus thrombosis (n = 1), postvaccination syndrome (n = 1) |
| ChAdOx1 nCoV-19    | Single recombinant, replication-deficient adenovirus vector                  | Two 0.5-mL doses, 28–84 days apart; each dose contains 2.5 × 10⁸ infectious units [57] | 70.4% efficacy at 14 days in all participants (N = 11,636⁵⁷): COVID illness in 101/5829 with placebo and 30/5807 with ChAdOx1 nCoV-19 [172] | AE at any time during study with ChAdOx1 nCoV-19 (N = 12,021⁵⁷) [172] |
| (AZD12222; AstraZeneca and Oxford Vaccine Group) | encoding unmodified SARS-CoV-2 spike protein                                  |                                                      | 62.1% efficacy at 14 days in participants (n = 8895) who received 2 standard doses (5 × 10¹⁰ vp) | Any serious AE (n = 79; 0.7%) including diarrhea (n = 1; < 0.1%), pain (0), pyrexia (n = 1; < 0.1%), vomiting (n = 1; < 0.1%) |
|                    |                                                                              |                                                      | 90.0% efficacy in participants (n = 2741) who received 1 low dose (2.5 × 10¹⁰ vp) and 1 standard dose | AEs of special interest: anaphylactic reaction (n = 1; < 0.1%), neuralgia (n = 2; < 0.1%), neuritis (n = 1; < 0.1%), neuropathy peripheral (n = 1; < 0.1%), facial paralysis (n = 3; < 0.1%), MS (n = 1; < 0.1%), myelitis transverse (n = 1; < 0.1%) |
patients with MS treated with ocrelizumab also experienced decreases in IgG and IgM antibodies below the lower limit of normal 96–120 weeks after starting treatment with ocrelizumab, which is predictable on the basis of the mechanism of action of this therapy [123]. A single case report of loss of vaccinal immunity against varicella zoster virus suggests that ocrelizumab may impair varicella vaccines; however, this finding needs to be replicated in a larger cohort [150].

Interest in off-label treatment with rituximab for MS has increased [153, 154], but vaccination studies in patients with MS have not occurred to date. However, registry data (N = 822) show that 3% of patients with MS experience reductions in IgG below the lower limit of normal at some point during treatment [155]. Two systematic review and meta-analysis studies found

## Table 5 continued

| Vaccine          | Description                                                                 | Administration                      | Efficacy (primary endpoint)                                      | Safety                                                                 |
|------------------|-----------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------------|
| NVX-CoV2373      | Subunit recombinant SARS-CoV-2 nanoparticle vaccine, constructed from the full-length wild-type SARS-CoV-2 spike protein altered by 2 proline substitutions; in Matrix M adjuvant [50, 51] | 5–50 µg doses; 1 or 2 doses (administered 21 days apart) in clinical trial [51] | No efficacy data available                                          | AE$s (n = 83)$ occurring after dose 2 included [51]                   |
|                  |                                                                             |                                     | At day 35 after first vaccination, two 5-µg doses (n = 29) induced geometric mean anti-spike IgG ELISA levels and higher neutralization responses than those in convalescent serum from COVID-19 patients (mostly symptomatic) | Local: pain (grade 2, 7.7–12.5%), erythema or redness (grade 2, 3.8–33.3%), induration or swelling (grade 2, 3.8%), tenderness (grade 2, 23.1–33.3%; grade 3, 4.2%) |
|                  |                                                                             |                                     | Adjuvanted regimens induced CD4$^+$ T cell responses [51]       | Systemic: joint pain/arthralgia (grade 2, 3.8–4.8%; grade 3, 3.8–8.3%), fatigue (grade 2, 4.8–19.2%; grade 3, 3.8–8.3%), malaise (grade 2, 4.8–16.7%; grade 3, 8.3%), headache (grade 2, 4.8–16.7%; grade 3, 4.0%), muscle pain/myalgia (grade 2, 8.3–11.5%; grade 3, 3.8–8.3%), nausea or vomiting (grade 3, 4.0%) |

Additional vaccine candidates are in various stages of clinical development and details can be found on the World Health Organization website [159].

AE adverse event, ELISA enzyme-linked immunosorbent assay, LNP lipid nanoparticle, mRNA messenger RNA, PCR, polymerase chain reaction, vp virus particles

$^a$ Participants who received BNT162b2 or placebo as randomly assigned had no evidence of infection within 7 days after second dose and no major protocol deviations

$^b$ Reactogenicity subset; includes recipients of either BNT162b2 or placebo

$^c$ Includes participants who received ≥ 1 dose of BNT162b2, irrespective of follow-up or follow-up time

$^d$ Per-protocol population

$^e$ Solicited safety set

$^f$ Incidences of 20.2/100,000 person-years over 5 years to cumulative incidence of 53.3/100,000 per year in the general population [173, 174]

$^g$ Per-protocol at risk set (excludes participants who had a positive PCR test between day 1 and day 14)

$^h$ Safety subset

$^i$ Primary efficacy population

$^j$ Participants who received ≥ 1 dose of vaccine

$^k$ Participants who received 1 or 2 doses of NVX-CoV2373 with or without adjuvant
a reduced response to pneumococcal vaccination [156, 157] and influenza vaccine [157] in patients with rheumatoid arthritis treated with rituximab but not for those who received anti-tumor necrosis factor alpha (TNFα) agent. Similarly, in a systematic review of studies in patients with rheumatoid arthritis or other inflammatory rheumatic diseases, rituximab also significantly decreased responses to an influenza vaccine, with tenfold lower hemagglutination inhibition assay titers observed in those administered rituximab less than 12 weeks before vaccination versus those administered rituximab more than 24 weeks before vaccination [158]. A second dose of the vaccine was needed to achieve responses comparable to those achieved with a single dose in healthy controls. No studies on vaccines are available for ofatumumab.

Data on alemtuzumab suggest vaccination should occur at least 6 months before starting treatment because depletion of T and B cells, as occurs with alemtuzumab treatment, would diminish response to vaccination [151].

The one study that included the DNA disrupter mitoxantrone reported an almost complete lack of response to influenza vaccination [90]. No studies on vaccines are available for cladribine.

COVID-19 VACCINE TRIALS AND CONSIDERATIONS FOR PEOPLE WITH MS

Multiple COVID-19 vaccines are in development [159] and a number are already being administered worldwide. Many target the spike protein of SARS-CoV-2, a protein expressed on the surface of the virus that facilitates entry into host cells, with the goal of generating robust humoral and T cell responses [160, 161]. This protein binds to a receptor on the host cell surface and then causes the virus and host cell membranes to fuse [53, 162].

Three vaccines, BNT162b2 (developed by Pfizer and BioNTech), mRNA-1273 (developed by Moderna), and Ad26.COV2.S (VAC31518; JNJ-78436735; developed by Janssen Biotech), have received emergency use authorization but have not yet received approval from the US Food and Drug Administration at the time of this publication [163–165]. BNT162b2, mRNA-1273, and another vaccine, ChAdOx1 nCoV-19 (AZD12222; developed by AstraZeneca and Oxford Vaccine Group), have received conditional marketing authorization in the European Union [166, 167]. BNT162b2 and mRNA-1273 contain lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the SARS-CoV-2 full-length spike protein but modified by two proline mutations [53, 168], and are administered in two doses [169]. Ad26.COV2.S (VAC31518; JNJ-78436735), administered in a single dose, and ChAdOx1 nCoV-19, administered in two doses, are recombinant replication-deficient adenovirus vector vaccines encoding the spike protein gene [57–59].

Efficacy and safety data for these vaccines are shown in Table 5. Adverse events reported for all the vaccines included local reactions, such as pain at the site of administration, and systemic reactions that included headache, fever, and fatigue. Bell’s palsy (n = 3) was reported with mRNA-1273 and facial paralysis (n = 2), brachial radiculitis (n = 1), Guillain–Barré syndrome (n = 1), transverse sinus thrombosis (n = 1); postvaccination syndrome (n = 1) was reported with Ad26.COV2.S (VAC31518; JNJ-78436735) [59, 170]. Another candidate of interest is NVX-CoV2373 (developed by Novavax), a subunit recombinant nanoparticle created from the spike protein [50, 51]. No efficacy data are available yet; however, a small study showed inducement of anti-spike antibody and T cell responses [51] (Table 5).

Members of the MS community have expressed an interest in COVID-19 vaccination. A US online survey of people with MS in the spring of 2020, before any COVID-19 vaccines were available, found that approximately two-thirds of respondents were willing or moderately willing to be vaccinated [175]. However, analyses focusing specifically on MS subgroups have yet to occur, and it is unknown how many people with MS have participated in COVID-19 vaccine studies. Thus, current knowledge pertaining to COVID-19 vaccination in patients with MS is based on conventional vaccines and anecdotal experience in those who have
received the vaccine thus far. The percentage of seroconversion that is deemed sufficient for “protection” varies on the basis of what the vaccine/pathogen is, and people receiving certain DMTs may be able to mount some, albeit diminished, antibody response to vaccination. Duration of disease may also affect response to vaccination. Longer disease duration ($p = 0.040$; odds ratio = 0.910) has been associated with an insufficient response to influenza vaccine in people with MS treated with interferons, glatiramer acetate, natalizumab, fingolimod, and other DMTs [87]. These findings may be impacted not only by DMT but also by age, comorbidities, and other factors.

When thinking about the potential impact of MS DMTs on vaccine efficacy, the role of specific immune cell populations may be considered. For example, T cell signatures may be a more sensitive measure of past SARS-CoV-2 infection than antibody assays, as individuals with symptomatic infections or who required hospitalization had higher T cell responses [176]. This suggests that disease-specific memory T cells, in addition to antibody titers, may be measurable and reliable correlates of protection [176]. However, SARS-CoV-2-reactive CD4+ T cells have been reported in 35–60% of unexposed individuals, suggesting possible cross-reactive T cell recognition between other coronaviruses (e.g., common cold viruses) and COVID-19 [177–179]; the protective effect of such cross-reactive T cells is unclear.

Coronavirus-specific T cells from Middle Eastern respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) have been shown to have long-term persistence and contribute to protection [176, 180, 181]. Hence, DMTs that deplete or significantly impact T cells may affect the efficacy of potential COVID-19 vaccines. Moreover, the National Multiple Sclerosis Society advises waiting at least 12 weeks after the last dose of B cell-depleting treatment before vaccinating [80], as anti-CD20 antibodies (i.e., ocrelizumab) have been found to induce rapid and prolonged (up to 24 weeks) B cell depletion and attenuated humoral immune responsiveness to vaccination in people with MS [149]. Many clinicians advise their patients that if given a choice, they should receive a vaccine when available and worry about timing later. More data are needed to fully understand the necessity of the memory B cell population, an important target of anti-CD20 therapies, to drive persistent antibody responses for extended periods of time following vaccination. Delaying therapy to allow for a more robust B cell response to the COVID vaccine, only to potentially diminish this response when therapy is resumed, may be counterproductive. Lastly, the impact that B cell-depleting therapies may have on other components of the immune system, including T cells, may also need to be a consideration for vaccine administration.

Because of their persistence (as opposed to declining levels of antibodies), T cells may be the more important measure for determining the efficacy of COVID-19 vaccines. However, antibodies still clearly have a role in preventing future infection through neutralization of a virus before it can infect a cell. Indeed, vaccines are traditionally designed to elicit a very robust humoral immune response, in addition to a cellular immune response, to convey both protection from infection and prevention of disease. The COVID-19 vaccines are not an exception to this. Moreover, even if antibody titers decline, this does not negate the fact that memory B cells should still be present and able to contribute significantly to the prevention of future infection, highlighting the importance of maintaining adequate levels of both B cells and T cells during the vaccination period and beyond [45].

Although the evidence clearly demonstrates the importance of measuring and generating a T cell or cell-mediated response to COVID-19 vaccines (as evidenced by the detection of SARS-CoV-2-specific T cells in convalescent patients [182]), it is important to remember that the immune response is a coordinated effort that must be orchestrated by both T cells and B cells (or cell-mediated and humoral immunity), as evidenced by the essential role that B cells have been shown to play in the generation of T cell memory [39, 183].
SUMMARY/CONCLUSION

Infections can be associated with an increased risk of relapses or pseudo-relapses in people with MS. For this reason, vaccination is an important tool that should be utilized, whenever possible, to limit infection in this population. However, the use of DMTs, which alter various components of the immune response, may also reduce the vaccine immune response in people with MS. In light of the current COVID-19 global pandemic and the recent authorization of novel vaccines against COVID-19, a better understanding of how MS DMTs may alter the immune response to vaccination is greatly needed. This review highlights previous studies of vaccine response in people with MS and focuses on how immunological impairment driven by various DMTs may impact successful vaccination strategies against COVID-19 in this patient population.

Immunological studies have shown that the coordinated interactions between T and B lymphocytes of the adaptive immune system are integral to the successful generation of immunological memory and production of neutralizing antibodies, following recognition of vaccine antigens by innate immune cells. CD4+ T cells play an essential role in facilitating both CD8+ T cell and B cell activation, but the inverse is also true, with B cells playing an important role in driving and sustaining T cell memory.

Previous studies of the immune response to vaccines other than COVID-19 in people with MS receiving various DMTs (Table 2) have shed some light on the key question of how each DMT or class of DMTs might affect the efficacy of a COVID-19 vaccine. Indeed, the data suggest that type 1 interferons, glatiramer acetate, and possibly teriflunomide may not significantly impair the response to vaccination, as opposed to those DMTs that rely on sequestration or depletion of large populations of immune cells, including S1P receptor modulators, alemtuzumab, cladribine, and anti-CD20 therapies. Other factors that could impact vaccine efficacy, including age and comorbidities, are beyond the scope of this review but should be considered. Benefits of vaccination, as outlined in guidance and guidelines from national and international MS groups, should be considered—even if vaccine efficacy may be compromised—when disease burden is high.

ACKNOWLEDGEMENTS

Funding. Biogen provided funding for this review and the journal’s Rapid Service and Open Access Fees.

Medical Writing and Editorial Assistance. Meryl Mandle from Excel Medical Affairs wrote the first draft of the manuscript based on input from the authors, and Nathaniel Hoover and Jackie Parker from Excel Medical Affairs copyedited and styled the manuscript per journal requirements. Biogen provided funding for the medical writing support.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authors’ Contributions. Anne Gocke and Megan Vignos were involved with the conception and design of the work. Megan Vignos was involved in searches of the literature. Patricia K. Coyle, Anne Gocke, Megan Vignos, and Scott D. Newsome interpreted data for the work, reviewed and revised the work critically for important intellectual content, and provided final approval of the version to be published.

Disclosures. Patricia K. Coyle receives consulting and nonbranded speaker fees from Accordant, Biogen, Bristol-Myers Squibb, Celgene, Genzyme/Sanofi, GlaxoSmithKline, Johnson & Johnson, Novartis, and Viela Bio; receives research support from Actelion, Alkermes, Celgene, Corrona, Genentech/Roche, MedDay, NINDS, and Novartis. Anne Gocke and Megan Vignos are employees of and own stock/stock options in Biogen. Scott D. Newsome has received
consultant fees for scientific advisory boards from Biogen, Genentech, Bristol-Myers Squibb, EMD Serono, Novartis, Greenwich Biosciences; is an advisor for Autobahn Therapeutics and BioIncept; is a clinical adjudication committee member for a MedDay Pharmaceuticals clinical trial; and has received research funding (paid directly to institution) from Biogen, Novartis, Genentech, National MS Society, Department of Defense, and Patient Centered Outcomes Institute.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.
2. Javalkar V, McGee J, Minagar A. Chapter 1—clinical manifestations of multiple sclerosis: an overview. In: Minagar A, editor. Multiple sclerosis: a mechanistic view. Academic; 2016. p. 1–12.
3. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21.
4. MS International Federation. Atlas of MS. 2020. https://www.atlasofms.org/map/united-states-of-america/epidemiology/number-of-people-with-ms. Accessed Nov 13, 2020.
5. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–36.
6. Castelo-Branco A, Chiesa F, Conte S, et al. Infections in patients with multiple sclerosis: a national cohort study in Sweden. Mult Scler Relat Disord. 2020;45:102420.
7. Persson R, Lee S, Ulcickas Yood M, et al. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord. 2020;41:101982.
8. Nelson RE, Xie Y, DuVall SL, et al. Multiple sclerosis and risk of infection-related hospitalization and death in US veterans. Int J MS Care. 2015;17(5):221–30.
9. Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis. 2018;5(8):ofy174.
10. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci. 2007;256(Suppl 1):S5-13.
11. Steelman AJ. Infection as an environmental trigger of multiple sclerosis disease exacerbation. Front Immunol. 2015;6:520.
12. Oikonen M, Laaksonen M, Aalto V, et al. Temporal relationship between environmental influenza A and Epstein–Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler. 2011;17(6):672–80.
13. Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(Pt 5):952–60.
14. National Multiple Sclerosis Society. COVID-19 vaccine guidance for people living with MS. 2021. https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance. Accessed Feb 1, 2021.
15. National Multiple Sclerosis Society. Immunization. https://www.nationalmssociety.org/For-
16. Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019;93(13):584–94.

17. Lebrun C, Vukusic S, French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SFSEP). Immunization and multiple sclerosis: recommendations from the French Multiple Sclerosis Society. Mult Scler Relat Disord. 2019;31:173–88.

18. Riva A, Barcella V, Benatti SV, et al. Vaccinations in patients with multiple sclerosis: a Delphi consensus statement. Mult Scler. 2021;27(3):347–59.

19. MS International Federation. MS, the coronavirus and vaccines—updated global advice. 2021. https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-you-need-to-know/. Accessed Feb 1, 2021.

20. Multiple Sclerosis Association of America. Vaccination safety in MS. 2020. https://mymsaa.org/PDFs/vaccine-safety.pdf. Accessed Jan 15, 2021.

21. Longbrake EE, Cross AH. Effect of multiple sclerosis disease-modifying therapies on B cells and humoral immunity. JAMA Neurol. 2016;73(2):219–25.

22. Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler. 2016;22(8):1061–70.

23. Sepúlveda M, Llufriu S, Martínez-Hernández E, et al. Incidence and impact of COVID-19 in MS: a survey from a Barcelona MS unit. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e954.

24. Zabalza A, Cárdenas-Robledo S, Tagliani P, et al. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14690.

25. Evangelou N, Garjani A, dasNair R, et al. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. J Neurol Neurosurg Psychiatry. 2020;92(1):107–9.

26. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Situation by country, territory and area. https://covid19.who.int/table?tableChartType=heat. Accessed Feb 24, 2021.

27. Möhn N, Konen FF, Pul R, et al. Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases. J Clin Med. 2020;9(12):4067.

28. Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021. https://doi.org/10.1002/ana.26028.

29. Johns Hopkins University of Medicine. Coronavirus resource center mortality analysis. https://coronavirus.jhu.edu/data/mortality. Accessed Apr 13, 2021.

30. Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of DMT therapies with COVID-19 severity in multiple sclerosis. medRxiv. 2021. https://doi.org/10.1101/2021.02.08.21251316.

31. Reder A, Centonze D, Naylor ML, et al. COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs. 2021;35:317–30.

32. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis. JAMA Neurol. 2021. https://doi.org/10.1001/jamaneurol.2021.0688.

33. Mateen FJ, Rezaei S, Alakel N, Gazdag B, Kumar AR, Vogel A. Impact of COVID-19 on US and Canadian neurologists’ therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices. J Neurol. 2020;267(12):3467–75.

34. Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S24-32.

35. Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):49.

36. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.

37. Janeway CAJ, Travers P, Walport M, Shlomchik MJ. Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Science; 2001.

38. Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73–8.

39. Petersone L, Edner NM, Ovcinnikovs V, et al. T cell/ B cell collaboration and autoimmunity: an intimate relationship. Front Immunol. 2018;9:1941.
40. Siegrist C-A. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders; 2013. p. 14–32.

41. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4 T cells: differentiation and functions. Clin Dev Immunol. 2012;2012:925135.

42. Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S33-40.

43. Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4 T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021;28(1–2):5–17.

44. Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol. 2017;188(2):183–94.

45. Siegrist C-A, Lambert P-H. Chapter 2—how vaccines work. In: Bloom BR, Lambert P-H, editors. The vaccine book. San Diego: Academic; 2016. p. 33–42.

46. Whitmire JK, Asano MS, Kaech SM, et al. Requirement of B cells for generating CD4 T cell memory. J Immunol. 2009;182(4):1868–76.

47. World Health Organization. WHO vaccine safety basics: learning manual. 2013. https://www.who.int/vaccine_safety/initiative/tech_support/Vaccine-safety-E-course-manual.pdf. Accessed Mar 3, 2021.

48. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509–17.

49. Yadav DK, Yadav N, Khuran SMP. Chapter 26—vaccines: present status and applications. In: Verma AS, Singh A, editors. Animal biotechnology. Oxford: Academic; 2014. p. 491–508.

50. Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(1):372.

51. Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–32.

52. Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol. 2013;25(2):152–9.

53. Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–71.

54. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.

55. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology. 2006;344(1):230–9.

56. Gilbert SC. T-cell-inducing vaccines—what’s the future. Immunology. 2012;135(1):19–26.

57. COVID-19 vaccine AstraZeneca suspension for injection. COVID-19 vaccine (ChAdOx1-S [recombinant]) [summary of product characteristics]. Södertälje: AstraZeneca AB; 2021.

58. Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5:91.

59. Janssen Biotech (a pharmaceutical company of Johnson & Johnson). COVID-19 vaccine Ad26.COV2.S VAC31518 (INJ-78436735). Sponsor briefing document. Vaccines and related biological products advisory committee. 2021. https://www.fda.gov/media/146219/download. Accessed Feb 26, 2021.

60. Maki J, Guiot AL, Aubert M, et al. Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG®): a global review. Vet Res. 2017;48(1):57.

61. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.

62. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), suspension for intramuscular injection. Research Triangle Park: GlaxoSmithKline Biologicals; 2019.

63. Lobaina Mato Y. Nasal route for vaccine and drug delivery: features and current opportunities. Int J Pharm. 2019;572:118813.

64. Lemoine C, Thakur A, Krajišnik D, et al. Technological approaches for improving vaccination compliance and coverage. Vaccines (Basel). 2020;8(2):304.

65. Li AV, Moon JJ, Abraham W, et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med. 2013;5(204):204ra130.

66. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly—TFH cells in human health and disease. Nat Rev Immunol. 2013;13(6):412–26.
67. Centers for Disease Control and Prevention. Immunization schedules. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html. Accessed Mar 9, 2021.

68. Ayling K, Vedhara K, Fairclough L. Measuring vaccine responses in the multiplex era. In: Yan Q, editor. Psychoneuroimmunology: methods and protocols. 2nd ed. New York: Springer; 2018. p. 327–40.

69. Zacour M, Ward BJ, Brewer A, et al. Standardization of hemagglutination inhibition assay for influenza serology allows for high reproducibility between laboratories. Clin Vaccine Immunol. 2016;23(3):236–42.

70. Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):e00084-e118.

71. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. 2007. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-data-needed-support-licensure-pandemic-influenza-vaccines. Accessed Mar 3, 2021.

72. Ong EZ, Chan YFZ, Leong WY, et al. A dynamic immune response shapes COVID-19 progression. Cell Host Microbe. 2020;27(6):879-82.e2.

73. Gil-Etayo FJ, Suárez-Fernández P, Cabrera-Marante O, et al. T-helper cell subset response is a determining factor in COVID-19 progression. Front Cell Infect Microbiol. 2021;11:624483.

74. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity. 2010;33(4):S16–29.

75. Yang WH, Dionne M, Kyle M, et al. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. Vaccine. 2013;31(40):4389–97.

76. Pereira B, Xu XN, Akbar AN. Targeting inflammation and immunosenescence to improve vaccine responses in the elderly. Front Immunol. 2020;11:583019.

77. Kurupati R, Kossenkov A, Haut L, et al. Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood. Oncotarget. 2016;7(39):62898–911.

78. Löbemann M, Borso D, Hilgendorf I, Fritzsche C, Zettl UK, Reisinger EC. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012;11(3):212–8.

79. American Academy of Neurology. Position statement on COVID-19 vaccination. https://www.aan.com/policy-and-guidelines/policy/position-statements/aan-position-statement-on-covid-19-vaccination/. Accessed Feb 2, 2021.

80. National Multiple Sclerosis Society. Timing MS medications with COVID-19 mRNA vaccines. https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-mRNA-Vaccines. Accessed Apr 19, 2021.

81. Société Francophone de la Sclérose En Plaques. MS/NMOSD recommendations and COVID19 vaccines [French]. 2020. https://sfsep.org/recommandations-sep-nmosd-et-vaccins-anti-covid19/. Accessed Feb 2, 2021.

82. Association of British Neurologists. Guidance on vaccination for COVID-19 and neurological conditions. 2021. https://www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/ABN_Guidance_on_COVID-19_Vaccinations_for_people_with_neurological_conditions_9.1.21.pdf. Accessed Mar 1, 2021.

83. Morabadi NF, Niewiesk S, Kruse N, et al. Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology. 2001;56(7):938–43.

84. Nguyen J, Hardigan P, Kesselman MM, Demory BM. Immunogenicity of the influenza vaccine in multiple sclerosis patients: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021;48:102698.

85. von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflam. 2017;5(1):e409.

86. Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81(6):552–8.

87. Metze C, Winkelmann A, Loebermann M, et al. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. CNS Neurosci Ther. 2019;25(2):245–54.

88. Mehling M, Fritz S, Hafner P, et al. Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy. PLoS ONE. 2013;8(11):e78532.
89. Schwid SR, Decker MD, Lopez-Bresnahan M, Rebif-Influenza Vaccine Study Investigators. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005;65(12):1964–6.

90. Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler. 2014;20(8):1074–80.

91. Hedegaard CJ, Krakauer M, Bendtzen K, Sørensen PS, Sellebjerg F, Nielsen CH. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Clin Immunol. 2008;129(1):80–9.

92. Severa M, Farina C, Salvetti M, Coccia EM. Three decades of interferon-β in multiple sclerosis: can we repurpose this information for the management of SARS-CoV2 infection? Front Immunol. 2020;11:1459.

93. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103.

94. Patterson JB, Thomis DC, Hans SL, Samuel CE. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology. 1995;210(2):508–11.

95. Silverman RH. Viral encounters with 2’,5’-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol. 2007;81(23):12720–9.

96. Samuel CE. Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses. J Biol Chem. 2019;294(5):1710–20.

97. Grebenciucova E, Pruitt A. Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep. 2017;17(11):88.

98. BETASERON (interferon beta-1b) for injection, for subcutaneous use. Whippany: Bayer HealthCare Pharmaceuticals; 1993.

99. AVONEX (interferon beta-1a) injection, for intramuscular injection. Cambridge: Biogen; 2020.

100. EXTAVIA® (interferon beta-1b) for injection, for subcutaneous use. East Hanover: Novartis; 2020.

101. REBIF (interferon beta-1a), for subcutaneous injection. Rockland: EMD Serono; 2020.
118. Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014;30(2):251–62.
119. VUMERITY® (diroximel fumarate) delayed-release capsules, for oral use. Cambridge: Biogen; 2020.
120. BAFIERTAM™ (monomethyl fumarate) delayed-release capsules, for oral use. High Point: Banner Life Sciences; 2020.
121. TYSABRI (natalizumab) injection, for intravenous use. Cambridge: Biogen; 2015–2020.
122. Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007;3(2):259–68.
123. OCREVUS® (ocrelizumab) injection, for intravenous use. South San Francisco: Genentech; 2020.
124. KESIMPTA® (ofatumumab) injection, for subcutaneous use. East Hanover: Novartis Pharmaceuticals; 2020.
125. RITUXAN® (rituximab) injection, for intravenous use. South San Francisco: Genentech; 2019.
126. LEMTRADA® (alemtuzumab) injection, for intravenous use. Cambridge: Genzyme; 2017.
127. Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol. 2013;4(4):1000152.
128. MAVENCLAD® (cladribine) tablets, for oral use. Rockland: EMD Serono; 2019.
129. NOVANTRONE® (mitoxantrone for injection concentrate). Rockland: EMD Serono; 2012.
130. Olfberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2018;25(3):527–34.
131. Winkelmann A, Metze C, Frimmel S, Reisinger EC, Zelti UK, Loebermann M. Tick-borne encephalitis vaccination in multiple sclerosis: a prospective, multicenter study. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e664.
132. Proietti E, Bracci L, Puzzoli S, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol. 2002;169(1):375–83.
133. Day SL, Ramsay IA, Ramsay AJ, Ranasinghe C. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol. 2008;180(11):7158–66.
134. Bar-Or A, Wiendl H, Miller B, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e70.
135. Mehling M, Hilpert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol. 2011;69(2):408–13.
136. Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84(9):872–9.
137. Mehling M, Eichin D, Hafner P, Höniger G, Kappos L, Hess C. Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS. Neurol Neuroimmunol Neuroinflamm. 2014;1(3):e28.
138. Signoriello E, Bonavita S, Sinisi L, et al. Is antibody titer useful to verify the immunization after VZV vaccine in MS patients treated with fingolimod? A case series. Mult Scler Relat Disord. 2020;40:101963.
139. Boulton C, Meiser K, David OJ, Schmouder R. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. J Clin Pharmacol. 2012;52(12):1879–90.
140. Berger JR. Varicella vaccination after fingolimod: a case report. Mult Scler Relat Disord. 2013;2(4):391–4.
141. Issa NP, Hentati A. VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology. 2015;84(1):99–100.
142. Connor LM, Harvie MC, Rich FJ, et al. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur J Immunol. 2010;40(9):2482–92.
143. Ciabattini A, Pettini E, Fiorino F, Prota G, Pozzi G, Medaglini D. Distribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in mice. PLoS ONE. 2011;6(4):e19346.
144. Flo‘rido M, Muflihah H, Lin LCW, et al. Pulmonary immunization with a recombinant influenza A virus vaccine induces lung-resident CD4+ memory T cells that are associated with protection against tuberculosis. Mucosal Immunol. 2018;11(6):1743–52.
145. Ufer M, Shakeri-Nejad K, Gardin A, et al. Impact of siponimod on vaccination response in a randomized, placebo-controlled study. Neuro Immunol Neuroinflamm. 2017;4(6):e398.

146. Sheffield JK, Janjua A, Campagnolo D, Raghupathi K, Agafonova N, Cree BAC. Incidence and outcomes of varicella zoster virus (VZV) reactivation in the ozanimod phase-3 clinical program (SUNBEAM and RADIANCE) in relapsing multiple sclerosis (RMS). Eur J Neurol. 2018;25:S28.

147. Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014;341(1–2):22–7.

148. Vägberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012;34(7):730–3.

149. Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELoce study. Neurology. 2020;95(14):e1999-2008.

150. Rapisarda L, Valentino P, Barone S, et al. Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab. Clin Immunol. 2021;223:108554.

151. McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872–6.

152. Longbrake EE, Mao-Draayer Y, Cascione M, et al. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Mult Scler. 2020. https://doi.org/10.1177/1352458520937282.

153. Berntsson SG, Kristoffersson A, Bostrom I, Feresi-adou A, Burman J, Landtblom AM. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden—outlier or predecessor? Acta Neurol Scand. 2018;138(4):327–31.

154. Ineichen BV, Moridi T, Granberg T,Piehl F. Rituximab treatment for multiple sclerosis. Mult Scler. 2020;26(2):137–52.

155. Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–81.

156. Hua C, Barnette C, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016–26.

157. van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis. Vaccine. 2018;36(39):5832–45.

158. Gabay C, Bel M, Combescore C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63(6):1486–96.

159. World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines. 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed Mar 5, 2021.

160. Watanabe Y, Allen JD, Wrapp D, McElhan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369(6501):330–3.

161. Funk CD, Laferrèrie C, Ardashani A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front Pharmacol. 2020;11:937.

162. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237–61.

163. US Food and Drug Administration. FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine [press release]. 2020. https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19. Accessed Dec 16, 2020.

164. US Food and Drug Administration. FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine [press release]. 2020. https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid. Accessed Dec 19, 2020.

165. US Food and Drug Administration. FDA issues emergency use authorization for third COVID-19 vaccine [press release]. 2021. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine. Accessed Mar 3, 2021.
166. AstraZeneca. COVID-19 Vaccine AstraZeneca authorised for use in the EU [press release]. 2021. https://www.astrazeneca.com/content/astrazeneca/media-centre/press-releases/2021/covid-19-vaccine-authorised-for-use-in-the-eu.html. Accessed Feb 1, 2021.

167. European Medicines Agency. COVID-19 vaccines: authorised. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section. Accessed Mar 1, 2021.

168. Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2. bioRxiv. 2020. https://doi.org/10.1101/2020.12.11.421008.

169. US Food and Drug Administration. FDA statement on following the authorized dosing schedules for COVID-19 vaccines [press release]. 2021. https://www.fda.gov/news-events/press-announcements/fda-statement-following-authorized-dosing-schedules-covid-19-vaccines. Accessed Jan 14, 2021.

170. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.

171. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.

172. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.

173. Monini S, Lazzarino AI, Iacolucci C, Buffoni A, Barbara M. Epidemiology of Bell’s palsy in an Italian Health District: incidence and case-control study. Acta Otorhinolaryngol Ital. 2010;30(4):198.

174. Rowlands S, Hooper R, Hughes R, Burney P. The epidemiology and treatment of Bell’s palsy in the UK. Eur J Neurol. 2002;9(1):63–7.

175. Ehde DM, Roberts MK, Herring TE, Alschuler KN. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States. Mult Scler Relat Disord. 2021;49:102788.

176. Gittelman RM, Lavezzo E, Snyder TM, et al. Diagnosis and tracking of past SARS-CoV-2 infection in a large study of Vo’i, Italy through T-cell receptor sequencing. medRxiv. 2021. https://doi.org/10.1101/2021.11.09.20228023.

177. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370(6512):89–94.

178. Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270–4.

179. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-501.e15.

180. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88(19):11034–44.

181. Zhao J, Alshukairi AN, Baharoon SA, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol. 2017;2(14):eaan5393.

182. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971-7.e3.

183. Marino J, Gonzalez-Nolasco B, Wang X, Orent W, Benichou G. Contrast effects of B cell depletion on CD4+ and CD8+ memory T cell responses generated after transplantation. Am J Transplant. 2020;20(9):2551–8.